Estimating the incidence of atrial fibrillation in single-chamber implantable cardioverter defibrillator patients by Zweibel, Steven et al.








Estimating the incidence of atrial fibrillation in single-chamber implantable
cardioverter defibrillator patients
Zweibel, Steven ; Cronin, Edmond M ; Schloss, Edward J ; Auricchio, Angelo ; Kurita, Takashi ; Sterns,
Laurence D ; Gerritse, Bart ; Lexcen, Daniel R ; Cheng, Alan
Abstract: BACKGROUND Atrial arrhythmias are associated with major adverse cardiovascular events.
Recent reports among implantable cardioverter defibrillator (ICD) patients have demonstrated a high
prevalence of atrial fibrillation (AF), predominantly in dual-chamber recipients. AF incidence among pa-
tients with single-chamber systems (approximately 50% of all ICDs) is currently unknown. The objective
was to estimate the prevalence of new-onset AF among single-chamber ICD patients by observing the
rates of new atrial tachycardia (AT)/AF among a propensity scoring matched cohort of dual-chamber ICD
patients from the PainFree SST study, to better inform screening initiatives. METHODS Among 2,770
patients enrolled, 1,862 single-chamber, dual-chamber, and cardiac resynchronization therapy (CRT) sub-
jects with no prior history of atrial tachyarrhythmias were included. Daily AT/AF burden was estimated
using a propensity score weighted model against data from dual-chamber ICDs. RESULTS Over 22 ±
9 months of follow-up, the estimated incidence of AT/AF - lasting at least 6 minutes, 6 hours and 24
hours per day - in the single-chamber cohort was 22.0%, 9.8% and 6.3%, whereas among dual-chamber
patients, the prevalence was 26.6%, 13.1%, and 7.1%, respectively. Initiation of oral anticoagulation
(OAC) was estimated to occur in 9.8% of the propensity matched single-chamber cohort, which was
higher than the actual observed rate of 6.0%. Stroke and transient ischemic attack (TIA) occurred at
low rates in all device subgroups. CONCLUSIONS Atrial arrhythmias occur frequently, and significant
underutilization of anticoagulation is suggested in single-chamber ICD recipients. Routine screening for
AF should be considered among single-chamber ICD recipients. This article is protected by copyright.
All rights reserved.
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Atrial arrhythmias are associated with major adverse cardiovascular events. Recent reports 
among implantable cardioverter defibrillator (ICD) patients have demonstrated a high prevalence of 
atrial fibrillation (AF), predominantly in dual-chamber recipients. AF incidence among patients with 
single-chamber systems (approximately 50% of all ICDs) is currently unknown. The objective was to 
estimate the prevalence of new-onset AF among single-chamber ICD patients by observing the rates 
of new atrial tachycardia (AT)/AF among a propensity scoring matched cohort of dual-chamber ICD 
patients from the PainFree SST study, to better inform screening initiatives. 
 
Methods  
Among 2,770 patients enrolled, 1,862 single-chamber, dual-chamber, and cardiac 
resynchronization therapy (CRT) subjects with no prior history of atrial tachyarrhythmias were 
included. Daily AT/AF burden was estimated using a propensity score weighted model against data 
from dual-chamber ICDs. 
 
Results 
Over 22 ± 9 months of follow-up, the estimated incidence of AT/AF - lasting at least 6 
minutes, 6 hours and 24 hours per day - in the single-chamber cohort was 22.0%, 9.8% and 6.3%, 
whereas among dual-chamber patients, the prevalence was 26.6%, 13.1%, and 7.1%, respectively. 
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single-chamber cohort, which was higher than the actual observed rate of 6.0%. Stroke and transient 
ischemic attack (TIA) occurred at low rates in all device subgroups. 
  
Conclusions 
Atrial arrhythmias occur frequently, and significant underutilization of anticoagulation is 
suggested in single-chamber ICD recipients. Routine screening for AF should be considered among 
single-chamber ICD recipients.  
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Co-morbidities that predispose to the development of systolic heart failure and 
sudden cardiac death often are also those that increase the risk for the development of 
atrial fibrillation (AF).
1-3









 recent attention has focused on identifying ways in which to more efficiently and effectively 




While the utility of screening the entire general population is controversial, most agree that 
identifying high risk populations to screen is justifiable since the prevalence within such groups may 
result in higher yield. Some experts support the use of opportunistic screening based on age alone
6
 but 
there are other populations that may benefit more including those with heart failure or individuals at 
increased risk for sudden cardiac death. In order to justify such efforts, an understanding of the true 
prevalence of AF in these populations is necessary. Individuals with implantable cardioverter 
defibrillators (ICDs) are one such population. In fact, among patients with dual-chamber ICDs, the 
incidence of newly detected atrial arrhythmias has been reported to be greater than 20% yearly across 
two separate investigations.7, 8 Since there is an increasing percentage of ICD patients undergoing 
implantation of a single-chamber system,
9
 these estimates may not be representative of the larger ICD 
population. The objective of this analysis was to estimate the incidence of newly detected AT/AF 
among single-chamber ICD recipients by observing the rates of new AT/AF among a propensity 




Study design and patients 
PainFree SST was a large multicenter clinical trial that aimed to evaluate if SmartShock
®
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primary results have been published previously.
10, 11
 The study was performed in compliance with the 
Declaration of Helsinki.
12
 The institutional review board of each participating center approved the 
study protocol, and all patients provided written informed consent. Among 2,770 patients implanted 
with a Medtronic Protecta
®
 (Medtronic plc, MN, U.S.) single-chamber, dual-chamber or cardiac 
resynchronization defibrillator (CRT-D) enrolled in the study, 1,862 subjects with no prior history of 
atrial arrhythmias (AF, atrial flutter, atrial tachycardia) were included in this analysis. 
 
Device data were downloaded at patient visits and used for this analysis. Newly detected 
episodes of AT/AF was determined by assessing total daily AT/AF burden (total AF duration/24 hour 
period) of atrial high rate events greater than 175 beats per minute for the preceding 425 days.
13
 
Endpoints for analysis of AT/AF incidence were the first day with a total AT/AF burden of 6 minutes, 
6 hours, 24 hours, and the first 7 consecutive days with 24 hours of AT/AF. Serious adverse events 
were collected only for patients enrolled from European sites 
11
 and were considered an AT/AF 
related complication if stroke, TIA, thrombosis or AT/AF was reported as a primary or secondary 
finding. 
 
Since no AT/AF data were collected in single-chamber ICD subjects, the likelihood that a 
single-chamber patient would develop new onset of AF was estimated from the incidence of AT/AF 
in dual-chamber patients. A propensity model was used to derive weights for the 649 dual-chamber 
patients, such that applying the weights would render the cohort comparable at baseline to the 574 
single-chamber patients. Incidence of AT/AF in the single-chamber cohort was then estimated by 
applying the same weights to the AT/AF incidence data of the dual-chamber patients. This will be 









To account for missing data, multiple imputation from the chained equations method was 
used to create 25 completed baseline data sets with any missing values randomly chosen from the 
distribution of values that were plausible for the patient accounting for all other baseline 
characteristics. There were 2 variables with more than 3 missing values: left ventricular ejection 
fraction (LVEF) in 101 patients (8.3%) and QRS duration in 94 patients (7.7%). 
 
Logistic regression was used to model the probability that a patient received a single-chamber 
ICD accounting for baseline characteristics (the propensity). All characteristics with a significant 
baseline difference were included, as well as gender, LVEF, New York Heart Association (NYHA) 
functional class, coronary artery disease, congestive heart failure, prior ventricular fibrillation (VF), 
treatment with angiotensin converting enzyme (ACE) inhibitor or angiotensin-II-receptor blocker 
(ARB), beta-blocker, diuretic, calcium channel blocker, or anti-coagulant. 
 
Analysis of AT/AF incidence used survival analysis methods including weighted and 
unweighted Kaplan-Meier estimation. Dual-chamber ICD patients have a weight assigned depending 
on how likely the implantation of a single-chamber device would have been given the patient’s 
baseline characteristics. The weight is calculated as p / (1 – p), where p represents the probability of 
getting a single-chamber device (propensity). A weight of 1 is assigned to single-chamber patients and 
used for those analyses that compare single-chamber and weighted dual-chamber patients [Inverse 
Probability of Treatment Weighting (IPTW)].
14
 Results from weighted analysis of dual-chamber 









Among the 1,862 patients without a history of atrial tachyarrhythmias [AF, atrial flutter, AT], 
639, 649, and 574 patients received a CRT, dual-chamber, and single-chamber ICD system, 
respectively (Figure 1). The mean follow-up time for this cohort was 22 ± 9 months. Patient baseline 
characteristics are outlined in Table 1. While the overall makeup of the population is reflective of the 
major clinical trials, significant differences existed between the dual-chamber and single-chamber 
ICD subjects. 
 
Incidence rates of AT/AF among CRT and dual-chamber ICD patients for various degrees of 
AT/AT burden are displayed in Figure 2. Of note, the proportions of CRT or dual-chamber ICD 
patients who experienced at least one day with more than 6 hours of total AF duration were observed 
to be 16.3% and 13.1% at 24 months, respectively. The estimated incidence rate of AT/AF burden of 
at least 6 hours in the matched single-chamber cohort was 9.8%. Incidence of newly detected AT/AF 
varied strongly by endpoint definition used and by device type (Table 2). The largest proportion of 
subjects with AT/AF burden lasting 7 days was observed in the CRT group with a rate of 8.2%. 
However, when comparing rates of AT/AF lasting greater than 7 days between dual-chamber ICD and 
matched single-chamber ICD subjects, the observed and estimated rates were 3.8% and 3.4%, 
respectively. 
 
Initiation of OAC in subjects without a history of atrial tachyarrhythmias was observed in 
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incidence where new OAC initiation might be warranted was 9.8% whereas the actual observed rate 
of OAC initiation was 6.0 % (Figure 3). Of the total subjects receiving OAC, not all had device-
detected AT/AF. Initiation of OAC and newly detected AT/AF (defined as a day with > 6 hours of 
AT/AF) occurred simultaneously in 3.5% of the dual-chamber ICD cohort and was estimated to occur 
in 3.4% of the matched single-chamber ICD cohort. 
 
Stroke and transient ischemic attack (TIA) information were collected in the European 
patients (n = 677). At 24 months, there was a low rate of stroke or TIA in the CRT-D (2.2%) and 
dual-chamber ICD (2.5%) cohorts. Within the single-chamber ICD cohort, a rate of 0.8% was 
observed. The low event rate did not permit further analysis according to anticoagulation status. 
DISCUSSION  
AF is common and recent studies have demonstrated a high incidence over time.
15
 Utilizing 
data collected from the PainFree SST study and modeling with propensity-scored matching, this 
analysis of ICD patients without a prior history of atrial tachyarrhythmias demonstrate that (1) newly 
detected AT/AF is common, (2) AT/AF is estimated to occur in 22% of single-chamber ICD patients 
by two years from the date of implant, and (3) the incidence of newly detected AT/AF is comparable 
in single- and dual-chamber ICD patients even though it tends to be lower in single-chamber.. Taken 
together, the results extend our current understanding of AF among patients with devices and call 
attention to the need to identify ways to properly screen those at increased risk of AT/AF 
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In the present analysis, AT/AF burden lasting ≥ 6 minutes was observed in 29.7% of the 
CRT-D patients, 26.6% of the dual-chamber ICD patients and estimated to occur in 22.0% of 
propensity score matched single-chamber ICD patients within two years of device implantation. These 
results are consistent with a prior study
7
 that evaluated newly detected AF among pacemaker, ICD, 
and CRT patients stratified by stroke risk. Our findings expand upon previous investigations by 
highlighting the differences in newly observed AF observed across different ICD device types. 
 
The accuracy of the modeled rate of AF among single-chamber patients in our analysis is 
highly dependent on the degree of similarity between the dual- and single-chamber ICD patients. 
Since the propensity scores matching methodology took into account differences in baseline 
conditions, the influence of factors like AV block and SND were minimized as much as possible. 
While prior studies have suggested that atrial pacing may have a small role in reducing AF,
16
 the 
impact of this is likely low in this analysis given that only 12.9% of dual chamber patients had an 
indication for pacing. 
 
The overall incidence of AT/AF and rapid onset of newly detected AT/AF across all device 
types have important clinical implications. Without the presence of an atrial lead, the single-chamber 
population is limited by relying on symptoms or serendipitous detection to diagnose AF, whereas 
dual-chamber and CRT patients are constantly being monitored. Given the increased risk for stroke 
associated with device-detected AT/AF events, we observed a large proportion (22.0%) of the single-
chamber ICD population that could potentially benefit from continuous AF screening. Currently, 
single-chamber AF screening can only be done via a Visia AF Single Chamber ICD (Medtronic plc, 
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capable of detecting AT/AF 
17
 or a Linox Smart DX ICD lead and DX ICD (Biotronik, Berlin, 
Germany) which contains a floating atrial dipole to detect atrial signals.
18
 These technologies are 
likely to provide additional supporting evidence of the true AT/AF incidence in single-chamber 
subjects in the future, but current evidence is lacking. Another interesting observation was that the 
rate of newly detected AF of more than 6 minutes per day is much higher in the initial months post-
implant for all device types. There may be several explanations for this, but the most likely may be 
that patients receiving devices have underlying AF that was asymptomatic, or subclinical in nature. A 
sub analysis from the ASSERT trial demonstrated that previously undiagnosed subclinical AF is 
common in ICD and pacemaker populations.
19
 By implanting a device with continuous AF 
monitoring, it is likely there is an initial spike in AF detection occurring in patients who had 
undocumented subclinical AF at the time of implant.  
 
The duration of AT/AF that should trigger initiation of anticoagulation in device patients is 
controversial. Studies have demonstrated that device-detected episodes of AF ranging in duration 
from 5 minutes to 24 hours are associated with increased risk of stroke, with the clearest evidence for 
an increased risk for episodes of 24 hours or more. 
19
 A recent consensus document has recommended 
initiation of oral anticoagulation in appropriate device patients with > 5.5 hours of daily AF burden
20
 
while others have suggested shorter and longer AF durations dependent on a patient’s underlying risk 
for stroke. 
21
 Regardless of the actual cut-off used, our data demonstrate that AT/AF is common and 
steadily increases over time. 
We also analyzed the incidence of new initiation of OAC within the first 24 months and 
found that there was a gap between the actual use of OAC in the single-chamber ICD subjects (5.8%) 
versus the expected use of OAC in this group (9.8%). This is likely due to under detection of 
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is possible that detection of AT/AF in the single-chamber ICD population could have resulted in a 
higher rate of OAC initiation and reduction in thromboembolic events. Unfortunately, 
thromboembolic events were only collected in a subset of patients and occurred at a very low rate. 
Hence, no meaningful comparison could be made. 
 
Limitations 
 Our study has several limitations that should be considered when interpreting the results. In 
this analysis, device detected AT/AF was used and was not independently adjudicated.  Additionally, 
AT/AF may be under-detected by ICDs due to undersensing or over-detected due to oversensing of 
other signals. This may lead to systematic over- or underestimation of AT/AF incidence, or more 
likely, regression to the mean. Hence, we used the AT/AF burden metric rather than the duration of 
each episode to potentially account for brief periods of undersensing. Second, complete adverse event 
data, specifically stroke, were collected only in the European subset of patients, limiting statistical 
power for analysis of these events. Third, we were unable to report the CHADS2 or CHA2DS2-VASc 
scores as not all the necessary data points were collected at baseline. Finally, the propensity matching 
successfully balanced observed patient characteristics, but may not have accounted for factors that 
were not collected in PainFree SST.  The overall rate of atrial pacing by dual-chamber devices may 
have influenced the incidence rate of AT/AF and may serve as a confounding factor. 
 
Conclusions 
Atrial arrhythmias are common among single-chamber ICD recipients with 22.0%, 9.8% and 
6.3% developing an episode of at least 6 minutes/day, 6 hours/day and 24 hours/day, respectively, 
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ICD population than the predicted AT/AF incidence, suggesting a role for algorithms which can 
detect AT/AF in single-chamber ICDs to increase AT/AF detection and appropriate OAC initiation. 
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FIGURE LEGENDS 
Figure 1. Patient Flow Diagram 
 
Figure 2. Time to First Occurrence of Different Daily AT/AF Burdens among CRT, Dual-Chamber 
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Figure 3.  Incidence of New Oral Anticoagulation. The bars represent incidence of new oral 
anticoagulation (OAC) initiation in the first 24 months, estimated with the Kaplan-Meier method. 












Table 1. Baseline Characteristics for all 1,862 CRT, Dual-Chamber and Single-Chamber Subjects 
Patient characteristics at baseline 
CRT-D 
(N = 639) 
Dual-
chamber 
(N = 649) 
Single-
chamber 
(N = 574)        P-value* 
Demographics and Clinical 
Presentation 
    
Male (N, %) 468 (73.2%) 519 (80.0%) 456 (79.4%) 0.83 
Age (years) 66.5 ± 11.3 61.9 ± 13.0 60.0 ± 12.1 0.007 
LVEF (%) 27.9 ± 9.5 35.0 ± 14.9 33.6 ± 13.7 0.092 
QRS duration (msec) 152.5 ± 27.1 113.3 ± 27.1 105.4 ± 20.6 < 0.0001 
Secondary prevention (N, %) 108 (16.9%) 245 (37.8%) 185 (32.2%) 0.048 
NYHA class (N, %)    0.27 
I 31 (4.9%) 131 (20.2%) 157 (27.4%)  
II 198 (31.0%) 285 (43.9%) 259 (45.1%)  
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Patient characteristics at baseline 
CRT-D 
(N = 639) 
Dual-
chamber 
(N = 649) 
Single-
chamber 
(N = 574)        P-value* 
IV 15 (2.3%) 3 (0.5%) 4 (0.7%)  
No Heart Failure 27 (4.2%) 136 (21.0%) 79 (13.8%)  
     
History (N, %)     
Coronary artery disease** 382 (59.8%) 419 (64.6%) 376 (65.5%) 0.76 
Myocardial infarction 217 (34.0%) 255 (39.3%) 260 (45.3%) 0.037 
Congestive heart failure 313 (49.0%) 181 (27.9%) 177 (30.8%) 0.28 
Hypertension 344 (53.8%) 339 (52.2%) 252 (43.9%) 0.004 
Previous device, any 241 (37.7%) 176 (27.1%) 114 (19.9%) 0.003 
     
Conduction Defects (N, %)     
Sinus Node Dysfunction 40 (6.3%) 55 (8.5%) 14 (2.4%) <0.0001 
AV block 116 (18.2%) 93 (14.3%) 37 (6.4%) < 0.0001 
Left bundle branch block 381 (59.6%) 63 (9.7%) 35 (6.1%) 0.021 
Right bundle branch block 48 (7.5%) 46 (7.1%) 31 (5.4%) 0.24 
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Patient characteristics at baseline 
CRT-D 
(N = 639) 
Dual-
chamber 
(N = 649) 
Single-
chamber 
(N = 574)        P-value* 
ACE inhibitor / ARB 531 (83.1%) 471 (72.6%) 432 (75.3%) 0.30 
Aldosterone Antagonist 274 (42.9%) 178 (27.4%) 162 (28.2%) 0.80 
Beta-Blocker 550 (86.1%) 544 (83.8%) 487 (84.8%) 0.64 
Diuretic 520 (81.4%) 358 (55.2%) 306 (53.3%) 0.53 
Anti-Arrhythmic 79 (12.4%) 108 (16.6%) 61 (10.6%) 0.003 
Anticoagulant 95 (14.9%) 99 (15.3%) 81 (14.1%) 0.63 
Antiplatelet 416 (65.1%) 441 (68.0%) 401 (69.9%) 0.50 
LVEF, Left Ventricular Ejection Fraction; NYHA, New York Heart Association; AV, 
Atrioventricular; ACE, Angiotensin Converting Enzyme; ARB, Angiotensin II Receptor Blocker. 
* p-values are for comparison between single-chamber and dual-chamber ICDs. Tests used are 
Student t-test, Fisher exact test, and Cochran-Mantel-Haenszel test for NYHA class. 
** Coronary artery disease as reported is derived from checkboxes for ischemic cardiomyopathy, 
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Table 2: Incidence of AT/AF endpoints at 24 months estimated using the Kaplan-Meier method. 
Endpoints are based on AT/AF burden thresholds, and AT/AF-related complications in patients who 
had a first episode of AT/AF.   
AT/AF duration CRT-D Dual-Chamber Matched Single-
Chamber* 
≥ 6 minutes 29.7% (25.7% - 33.5%) 26.6% (22.8% - 30.2%) 22.0% (18.3% - 25.5%) 
≥ 6 hours 16.3% (13.0% - 19.4%) 13.1% (10.1% - 15.9%) 9.8% (7.1% - 12.4%) 
≥ 24 hours 9.9% (7.3% - 12.4%) 7.1% (4.9% - 9.3%) 6.3% (4.1% - 8.5%) 
≥ 7 days 8.2% (5.8% - 10.6%) 3.8% (2.1% - 5.5%) 3.4% (1.8% - 5.0%) 
AT/AF related 
complication** 
37.7% (26.2% - 47.4%) 34.9% (21.1% - 46.3%) 33.5% (19.7% - 44.9%) 
AF, Atrial Fibrillation; AT, Atrial Tachycardia 
*
 Single-Chamber was estimated by propensity score weighting of Dual-Chamber patients 
**
 Any serious adverse event with evidence of atrial fibrillation, thrombosis,   
stroke or transient ischemic attack which occurs after the first AT/AF episode 
 
 
